Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hochhaus, A, Masszi, T, Giles, F J, Radich, J P, Ross, D M, Gómez Casares, M T, Hellmann, A, Stentoft, J, Conneally, E, García-Gutiérrez, V, Gattermann, N, Wiktor-Jedrzejczak, W, le Coutre, P D, Martino, B, Saussele, S, Menssen, H D, Deng, W, Krunic, N, Bedoucha, V, Saglio, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508077/
https://www.ncbi.nlm.nih.gov/pubmed/28218239
http://dx.doi.org/10.1038/leu.2017.63

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508077/
https://www.ncbi.nlm.nih.gov/pubmed/28218239
http://dx.doi.org/10.1038/leu.2017.63

Ejemplares similares